A detailed history of Rhumbline Advisers transactions in Surmodics Inc stock. As of the latest transaction made, Rhumbline Advisers holds 20,999 shares of SRDX stock, worth $808,251. This represents 0.0% of its overall portfolio holdings.

Number of Shares
20,999
Previous 18,536 13.29%
Holding current value
$808,251
Previous $543,000 62.43%
% of portfolio
0.0%
Previous 0.0%

Shares

28 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 01, 2024

BUY
$25.39 - $42.1 $62,535 - $103,692
2,463 Added 13.29%
20,999 $882,000
Q1 2024

May 09, 2024

BUY
$27.44 - $35.56 $19,564 - $25,354
713 Added 4.0%
18,536 $543,000
Q4 2023

Feb 08, 2024

SELL
$28.47 - $38.49 $6,491 - $8,775
-228 Reduced 1.26%
17,823 $647,000
Q3 2023

Nov 09, 2023

SELL
$28.28 - $38.36 $1,979 - $2,685
-70 Reduced 0.39%
18,051 $579,000
Q2 2023

Aug 08, 2023

BUY
$17.67 - $31.31 $3,869 - $6,856
219 Added 1.22%
18,121 $567,000
Q1 2023

May 11, 2023

SELL
$17.13 - $38.52 $365,177 - $821,169
-21,318 Reduced 54.35%
17,902 $408,000
Q4 2022

Feb 14, 2023

BUY
$29.44 - $37.31 $24,641 - $31,228
837 Added 2.18%
39,220 $1.34 Million
Q3 2022

Nov 10, 2022

BUY
$28.84 - $38.92 $35,905 - $48,455
1,245 Added 3.35%
38,383 $1.17 Million
Q2 2022

Aug 11, 2022

BUY
$33.25 - $45.11 $10,374 - $14,074
312 Added 0.85%
37,138 $1.38 Million
Q1 2022

May 12, 2022

BUY
$40.68 - $49.72 $64,315 - $78,607
1,581 Added 4.49%
36,826 $1.67 Million
Q4 2021

Feb 10, 2022

SELL
$43.21 - $57.6 $11,018 - $14,688
-255 Reduced 0.72%
35,245 $1.7 Million
Q3 2021

Nov 12, 2021

SELL
$52.8 - $60.32 $290,875 - $332,302
-5,509 Reduced 13.43%
35,500 $1.97 Million
Q2 2021

Aug 05, 2021

SELL
$51.29 - $59.15 $51,443 - $59,327
-1,003 Reduced 2.39%
41,009 $2.23 Million
Q1 2021

May 06, 2021

BUY
$42.18 - $56.07 $29,610 - $39,361
702 Added 1.7%
42,012 $2.36 Million
Q4 2020

Feb 10, 2021

BUY
$35.18 - $43.52 $102,268 - $126,512
2,907 Added 7.57%
41,310 $1.8 Million
Q3 2020

Nov 12, 2020

SELL
$37.98 - $48.72 $62,249 - $79,852
-1,639 Reduced 4.09%
38,403 $1.49 Million
Q2 2020

Aug 13, 2020

SELL
$31.07 - $44.74 $272,452 - $392,325
-8,769 Reduced 17.97%
40,042 $1.73 Million
Q1 2020

May 06, 2020

SELL
$22.46 - $42.24 $138,982 - $261,381
-6,188 Reduced 11.25%
48,811 $1.63 Million
Q4 2019

Feb 05, 2020

BUY
$39.01 - $47.51 $99,397 - $121,055
2,548 Added 4.86%
54,999 $2.28 Million
Q3 2019

Oct 23, 2019

BUY
$38.66 - $47.41 $16,082 - $19,722
416 Added 0.8%
52,451 $2.4 Million
Q2 2019

Aug 14, 2019

BUY
$38.23 - $47.43 $406,423 - $504,228
10,631 Added 25.68%
52,035 $2.25 Million
Q1 2019

May 01, 2019

SELL
$41.26 - $58.35 $310,646 - $439,317
-7,529 Reduced 15.39%
41,404 $1.8 Million
Q4 2018

Jan 31, 2019

BUY
$44.93 - $73.38 $746,736 - $1.22 Million
16,620 Added 51.43%
48,933 $2.31 Million
Q3 2018

Nov 07, 2018

SELL
$56.85 - $80.35 $19,499 - $27,560
-343 Reduced 1.05%
32,313 $2.41 Million
Q2 2018

Aug 06, 2018

BUY
$35.85 - $57.05 $29,755 - $47,351
830 Added 2.61%
32,656 $1.8 Million
Q1 2018

May 02, 2018

BUY
$27.0 - $38.5 $17,766 - $25,333
658 Added 2.11%
31,826 $1.21 Million
Q4 2017

Feb 09, 2018

BUY
$28.0 - $33.2 $101,220 - $120,018
3,615 Added 13.12%
31,168 $873,000
Q3 2017

Nov 06, 2017

BUY
$24.5 - $31.1 $675,048 - $856,898
27,553
27,553 $854,000

Others Institutions Holding SRDX

About SURMODICS INC


  • Ticker SRDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Devices
  • Shares Outstandng 14,005,000
  • Market Cap $539M
  • Description
  • Surmodics, Inc., together with its subsidiaries, provides surface modification technologies for intravascular medical devices, and chemical components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates in two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device s...
More about SRDX
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.